03 July 2017
Reporter: Barney Dixon

Canadian Supreme Court rips up promise doctrine

The Canadian Supreme Court has ripped up the country’s controversial ‘promise doctrine’ and upheld AstraZeneca’s heartburn drug patent as valid in its case against Apotex.

Apotex attempted to sell a generic version of AstraZeneca’s heartburn drug, Nexium, to which AstraZeneca responded with a patent infringement lawsuit.

Canada’s Federal Court of Appeals held that AstraZeneca’s patent for the drug was “invalid for lack of utility because, applying the promise of the patent doctrine, it promised more than it could provide”.

The dispute then went to the Supreme Court, which ruled that the promise doctrine is “not the correct method of determining whether the utility requirement under Section 2 of the Canadian Patent Act is met”.

“The promise doctrine is incongruent with both the words and the scheme of the Patent Act.”

The US Chamber of Commerce’s Global Intellectual Property Center (GIPC) welcomed the decision, with vice president of international intellectual property policy, Patrick Kilbride, describing the “restrictive approach” of the doctrine as “making it difficult to obtain or defend a life sciences patents in Canada”.

“Today, the Supreme Court has begun to restore much-needed clarity and confidence that biopharmaceutical innovators will be afforded equal protections under the law,” he said. “This ruling sends an important signal that Canada is open for the business of innovation.”

According to the GIPC, since the creation of the promise doctrine in 2005, 26 patents that covered 22 innovative medicines have been overturned.

Earlier this year, Eli Lilly lost its North American Free Trade Agreement (NAFTA) dispute with Canada over the doctrine.

Eli Lilly claimed that the doctrine contravened Canada’s NAFTA obligations, but a panel said it didn’t amount to a denial of justice warranting investor-state arbitration.

At the time, Kilbride said the doctrine “dramatically undermines legal certainty for medical innovators in Canada”.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Baker Botts promotes three in IP
21 November 2017 | Texas | Reporter: Barney Dixon
Baker Botts has promoted three intellectual property attorneys to partner, as part of a round of 11 partner promotions
Alibaba in ITC spotlight
20 November 2017 | Washington DC | Reporter: Barney Dixon
Alibaba will be investigated by the US International Trade Commission over the importation and sale of insulated beverage containers, their labels, and packaging materials
MediaTek partners with Anaqua
20 November 2017 | Boston | Reporter: Barney Dixon
Taiwanese semiconductor company MediaTek has selected Anaqua to manage its intellectual property activities, including its inventions and patents
Brazil and China sign PPH agreement
17 November 2017 | Beijing | Reporter: Barney Dixon
The State Intellectual Property Office of China has signed a patent prosecution highway agreement with the Brazilian National Institution of Intellectual Property
Cozen O’Connor hires ex-DLA Piper litigator
17 November 2017 | Washington DC | Reporter: Barney Dixon
Cozen O’Connor has hired ex-DLA Piper litigator Hugh Marbury as member in its intellectual property department
Mewburn Ellis opens Munich office
16 November 2017 | Munich | Reporter: Barney Dixon
Intellectual property boutique Mewburn Ellis has opened a new office in Munich, its first expansion outside of the UK
EPO faces backlash over scrapping of permanent employment contracts
15 November 2017 | Munich | Reporter: Barney Dixon
In an internal memo, the Staff Union of the European Patent Office described the move as “Kafkaesque”